A trial of nebulised heparin to limit lung injury following cardiac surgery

Anaesthesia and Intensive Care

Volumn 44, Issue 1, 2016, Pages 28-33

  Dixon, B ^a   Smith, R ^a   Santamaria, J D ^a   Orford, N R ^b   Wakefield, B J ^b   Ives, K ^b   McKenzie, R ^b   Zhang, B ^c   Yap, C H ^c,d  

^a ST VINCENT S HOSPITAL   (Australia)

^b BARWON HEALTH   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

acute lung injury; cardiac surgery; fibrin; heparin; microvascular thrombosis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ADVERSE EFFECTS; AGED; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART SURGERY; HUMAN; LUNG INJURY; MALE; MIDDLE AGED; NEBULIZER; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HUMANS; LUNG INJURY; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS;

EID: 85003953001     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057X1604400106     Document Type: Article

References (25)

1. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S. Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis. Heart 2003; 89:767-772.
2. Rady MY, Ryan T, Starr NJ. Early onset of acute pulmonary dysfunction after cardiovascular surgery: risk factors and clinical outcome. Crit Care Med 1997; 25:1831-1839.
3. Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 2012; 308:1761-1767.
4. Chai PJ, Williamson JA, Lodge AJ, Daggett CW, Scarborough JE, Meliones JN et al. Effects of ischemia on pulmonary dysfunction after cardiopulmonary bypass. Ann Thorac Surg 1999; 67:731-735.
5. Lazar HL, Fitzgerald C, Gross S, Heeren T, Aldea GS, Shemin RJ. Determinants of length of stay after coronary artery bypass graft surgery. Circulation 1995; 92:1120-1124.
6. Stephens RS, Shah AS, Whitman GJR. Lung injury and acute respiratory distress syndrome after cardiac surgery. Ann Thorac Surg 2013; 95:1122-1129.
7. Kogan A, Preisman S, Levin S, Raanani E, Sternik L. Adult respiratory distress syndrome following cardiac surgery. J Card Surg 2014; 29:41-46.
8. Dixon B, Nixon I, Kenny J, Newcomb AE, Rosalion A, Opeskin K et al. Aprotinin, but not tranexamic acid, is associated with increased pulmonary microvascular fibrin deposition after cardiac surgery. Thromb Res 2011; 127:272-274.
9. Dixon B, Opeskin K, Stamaratis G, Nixon I, Yi M, Newcomb AE et al. Pre-operative heparin reduces pulmonary microvascular fibrin deposition following cardiac surgery. Thromb Res 2011; 127:e27-e30.
10. Dixon B, Campbell DJ, Santamaria JD. Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery. Intensive Care Med 2008; 34:1216-1223.
11. Castro CY. ARDS and diffuse alveolar damage: a pathologist's perspective. Semin Thorac Cardiovasc Surg 2006; 18:13-19.
12. Dixon B, Smith R, Campbell DJ, Tobin A, Newcomb AE, Rosalion A et al. The effect of etanercept on lung leukocyte margination and fibrin deposition after cardiac surgery. Am J Respir Crit Care Med 2013; 188:751-754.
13. Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008; 12:R64.
14. Tangphao O, Chalon S, Moreno HJJr, Abiose AK, Blaschke TF, Hoffman BB. Heparin-induced vasodilation in human hand veins. Clin Pharmacol Ther 1999; 66:232-238.
15. Tasatargil A, Ogutman C, Golbasi I, Karasu E, Dalaklioglu S. Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin,and unfractioned heparin in human internal mammary artery. J Cardiovasc Pharmacol 2005; 45:550-554.
16. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993; 329:90-95.
17. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis KJr et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291:1603-1609.
18. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010; 14:R180.
19. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care 2010; 14:445.
20. Cadroy Y, Gaspin D, Dupouy D, Lormeau JC, Boneu B, Sie P. Heparin reverses the procoagulant properties of stimulated endothelial cells. Thromb Haemost 1996; 75:190-195.
21. Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D et al. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 1999; 81:589-593.
22. Pepe G, Giusti B, Attanasio M, Gori AM, Comeglio P, Martini F et al. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Semin Thromb Hemost 1997; 23:135-141.
23. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network.
24. Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT. Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med 1999; 160:1653-1658.
25. Mahadoo J, Hiebert LM, Jaques LB, Wright CJ. Endothelial sequestration of heparin administered by the intrapulmonary route. Artery 1980; 7:438-447.